BIONIK Laboratories Corp. Quarterly report pursuant to Section 13 or 15(d)

WARRANTS (Tables)

6 Months Ended

Sep. 30, 2019

The following is a continuity schedule of the Company’s common share purchase warrants:


		Weighted
		Average
	Number of	Exercise Price
	Warrants	($)
Outstanding and exercisable, March 31, 2018 and September 30, 2018	365,974	53.19
Issued in connection with anti-dilution provision connected warrant transaction	67,952	55.71
Issued in connection with anti-dilution provision connected warrant transaction	6,305	34.50
Issued in connection with anti-dilution provision connected warrant transaction	52,590	38.91
Expired	(204,304)	(51.85)
Outstanding and exercisable, March 31, 2019	288,517	40.27
Expired	(163,483)	(38.91)
Outstanding and exercisable, September 30, 2019	125,034	20.07

The following is a summary of common share purchase warrants outstanding as of September 30, 2019.